The Monjuvi therapy. Why MorphoSys still invests in this lymphoma drug

Monjuvi is poured slowly into the infusion bag, clear liquid catching the cold light of the hospital pharmacy as an oncology nurse checks the label one last time before hanging it at the bedside of a patient who has already tried several cancer regimens.

What Monjuvi is designed to do

Monjuvi is a CD19-directed monoclonal antibody that targets malignant B cells in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for an autologous stem cell transplant. The medicine is given in combination with lenalidomide, an immunomodulatory drug, as specified in its approved indication.

The therapy emerged from MorphoSys’s antibody development platform and is co-commercialized in the United States with partner Incyte, while Incyte holds marketing rights outside the US. The original US approval was granted by the Food and Drug Administration under the accelerated approval pathway in July 2020, based on overall response data from the single-arm L-MIND trial.

How Monjuvi is used in practice

In clinical routine, Monjuvi is administered intravenously in 28-day treatment cycles, with more frequent infusions in the initial cycles and less frequent dosing in later cycles for patients who continue to benefit. Before each infusion, patients typically receive premedication such as antihistamines and antipyretics to reduce the risk of infusion-related reactions, which are among the more common side effects.

In the L-MIND study, Monjuvi plus lenalidomide showed an overall response rate of around 60 percent in heavily pretreated DLBCL patients, with a substantial fraction achieving complete responses. These data have been central to regulators’ benefit-risk assessment in an indication where many patients have limited options once standard chemo-immunotherapy fails.

What the data and label say

According to the US prescribing information, Monjuvi is dosed at 12 mg per kg of body weight, administered as an intravenous infusion. The label warns about serious adverse reactions including infections, cytopenias such as neutropenia, and infusion-related reactions, as well as the need for regular monitoring of blood counts during treatment.

In L-MIND, the median duration of response was reported at more than one year for responders, an important outcome in a population that often measures treatment benefit in months. The study population consisted predominantly of patients who had received at least two prior lines of therapy, reflecting the difficult prognosis once first-line chemo-immunotherapy fails.

Strategic importance for MorphoSys

For MorphoSys, Monjuvi remains a central commercial asset, even though the company has recently shifted a lot of investor attention to its broader pipeline and transactions in hematology-oncology. In recent earnings presentations, management has repeatedly highlighted contributions from Monjuvi, particularly in the US market, as part of its revenue base.

MorphoSys CEO Jean-Paul Kress has described Monjuvi as an important therapy for patients with aggressive lymphoma who cannot proceed to transplant, emphasizing continued efforts together with Incyte to educate hematologists and expand its use within the approved indication. The drug sits alongside other assets and collaborations that shape the company’s evolving business model.

Pricing and availability

In the United States, Monjuvi is available as a concentrated solution for infusion in vials; pricing falls into the upper range typical for specialty oncology biologics, with final costs depending on dose, duration, and negotiated discounts. Access usually runs through hospital pharmacies and specialty distributors, and reimbursement often involves prior authorization by payers.

Outside the US, the medicine is commercialized by Incyte, and availability depends on national approvals and reimbursement decisions in individual countries. In some markets, authorities have assessed Monjuvi in health technology evaluations for relapsed or refractory DLBCL patients who lack alternatives, weighing survival benefits against therapy costs.

How doctors see Monjuvi in the toolkit

In lymphoma centers, physicians view Monjuvi plus lenalidomide as one of several targeted or cellular options for patients whose DLBCL comes back or does not respond, especially when stem cell transplant or CAR-T therapy is not possible. Treatment choice depends on age, comorbidities, prior regimens, and access to therapies such as CAR-T or other CD19-directed agents.

Hematologists also pay attention to overlapping toxicities when combining agents, particularly myelosuppression and infection risk when Monjuvi is used with lenalidomide. This means dose adjustments and supportive care become a routine part of managing patients over multiple cycles.

Competition in relapsed DLBCL

The market segment where Monjuvi plays is increasingly crowded, with CAR-T therapies, antibody-drug conjugates, and other CD19 or CD79b-targeted antibodies competing for often small, well-defined patient groups. This competition translates into pressure on prescribing and reimbursement, as payers compare efficacy data, safety profiles, and cost per patient.

Monjuvi’s differentiating point is its positioning for patients ineligible for autologous stem cell transplant and the option to treat in outpatient settings, which can be attractive for certain hospitals and patients. Still, as new data from competing regimens emerge, Monjuvi’s clinical role is regularly re-evaluated in guidelines and tumor boards.

Regulatory status and post-approval work

Because the original FDA approval of Monjuvi in DLBCL was granted under the accelerated approval pathway, MorphoSys and Incyte have obligations to provide further confirmatory data. Post-approval trials are designed to test whether the observed benefits hold up in larger or more comparative settings, which can influence label updates or continued authorization.

The companies also pursue regulatory processes outside the US, where agencies may request additional data or local analyses before granting or expanding indications. For investors, this means that Monjuvi’s long-term contribution depends not only on current sales but also on how these regulatory and clinical follow-up efforts progress.

Clinical handling and patient experience

From the patient’s perspective, an infusion day with Monjuvi often starts with the clinical smell of disinfectant in the day clinic and a nurse checking vital signs, blood counts, and premedication before the drug runs through a transparent line into the arm. Infusion times are initially longer and can be shortened in later cycles if the patient tolerates the therapy well.

Common side effects like fatigue, anemia, neutropenia, and infections can significantly shape daily life during treatment, leading to dose holds or reductions according to the prescribing information. Treating teams balance the aim of maintaining response with the need to keep side effects manageable.

Business impact and stock context

For MorphoSys, Monjuvi is more than a clinical story; it is also part of the revenue mix that underpins cash flows and partnership economics with Incyte. The MorphoSys AG stock (ISIN DE0006632003) reflects expectations on Monjuvi alongside the rest of the pipeline and cooperative projects.

en | DE0006632003 | MORPHOSYS AG | boerse | 69825438 |